![](https://news.europawire.eu/wp-content/uploads/2013/08/Professor-Klaus-Dugi.png)
Over 950 patients have now been successfully enrolled in the pivotal Phase III HCVerso™1 and 2 trials The Phase III study programme includes treatment naïve patients, including those ineligible for interferon and patients with liver cirrhosis The milestone coincides with … Read the full press release